91E04630-B2A7-448E-8C80-580818C9D7E6
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 18.429697766097238
- age_years
- 63
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.645
- MYC_TARGETS_V2+0.574
- INTERFERON_GAMMA_RESPONSE+0.571
- ANGIOGENESIS+0.559
- E2F_TARGETS+0.540
- MYC_TARGETS_V1+0.510
- G2M_CHECKPOINT+0.508
- DNA_REPAIR+0.439
- ALLOGRAFT_REJECTION+0.413
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.408
Top 10 suppressed
- KRAS_SIGNALING_DN-0.319
- HEDGEHOG_SIGNALING-0.262
- SPERMATOGENESIS-0.208
- ESTROGEN_RESPONSE_EARLY-0.166
- MYOGENESIS-0.160
- PANCREAS_BETA_CELLS-0.156
- BILE_ACID_METABOLISM-0.132
- HEME_METABOLISM-0.064
- UV_RESPONSE_DN-0.044
- FATTY_ACID_METABOLISM-0.043
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934839 | — | — | 0.951 |
| 2 | 2B311620-94F3-4B53-B66A-81AC0A32453B | — | — | 0.949 |
| 3 | 81B10E10-884A-46EB-9F28-758D805FB9B1 | — | — | 0.948 |
| 4 | FD3CFD0E-E8D9-4A57-A9F0-4FB519B7E459 | — | — | 0.948 |
| 5 | SRR934883 | — | — | 0.944 |
| 6 | SRR934874 | — | — | 0.944 |
| 7 | D1729A17-148B-4C58-BEB5-7C4349A0E920 | — | — | 0.943 |
| 8 | SRR934949 | — | — | 0.941 |
| 9 | AFE1F307-45A7-4155-8D51-FEBD6C92947C | — | — | 0.941 |
| 10 | 8B4E465B-0FD5-4154-824B-1E6B2656FD2F | — | — | 0.940 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.645 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.574 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.571 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.559 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.508 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.439 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.413 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.408 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.395 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.390 | Idelalisib | — uncovered |
| APOPTOSIS | 0.346 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.346 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.324 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.315 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.299 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.294 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.287 | Inavolisib | — uncovered |
| COMPLEMENT | 0.277 | Inavolisib | — uncovered |